Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Says Chinese Patent Office to Grant Patent on RNAi Molecules

Premium

Alnylam Pharmaceuticals this week announced that it has been notified that the Chinese patent office intends to grant a patent, assigned to the Max Plank Society and exclusively licensed to Alnylam, covering siRNAs.

According to the company, the patent application — No. 01820900.9 — is part of the so-called Tuschl II family of intellectual property and covers the compositions, methods, uses, and systems of double-stranded RNAs having key structural elements including a length of between 19 and 25 nucleotides; one or more 3' overhangs at the ends of the molecule; and chemical modifications on the 3' end.

The application also claims the use of such molecules to modulate gene function in mammals or pathogen-derived genes in vitro and in vivo, Alnylam said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.